Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study
B Löwenberg, J Beck, C Graux… - Blood, The Journal …, 2010 - ashpublications.org
In older patients with acute myeloid leukemia (AML), the prevention of relapse has remained
one of the major therapeutic challenges, with more than 75% relapses after complete …
one of the major therapeutic challenges, with more than 75% relapses after complete …
Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50–70 …
H Farhat, O Reman, E Raffoux… - American journal of …, 2012 - Wiley Online Library
This Phase 1/2 study aimed to determine optimal doses of daunorubicin (DNR; mg/m2) and
cytarabine (mg/m2) to be combined with fractionated doses of gemtuzumab ozogamicin …
cytarabine (mg/m2) to be combined with fractionated doses of gemtuzumab ozogamicin …
Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin
HK Duong, MA Sekeres - Clinical interventions in aging, 2009 - Taylor & Francis
As the overall prognosis and treatment response rate to standard chemotherapy for acute
myeloid leukemia (AML) remains poor in the older adult population, there is a need for more …
myeloid leukemia (AML) remains poor in the older adult population, there is a need for more …
Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia …
N Usui, A Takeshita, C Nakaseko, N Dobashi… - Cancer …, 2011 - Wiley Online Library
In order to investigate better molecular‐target therapy for acute myeloid leukemia (AML), we
conducted a phase I trial of a combination of gemtuzumab ozogamicin (GO) with …
conducted a phase I trial of a combination of gemtuzumab ozogamicin (GO) with …
Gemtuzumab ozogamicin (Mylotarg®) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a …
S Amadori, S Suciu, R Stasi, R Willemze, F Mandelli… - Leukemia, 2005 - nature.com
The therapeutic activity and toxicity profile of gemtuzumab ozogamicin were assessed in 40
patients> 60 years of age with acute myeloid leukemia (AML) who were not considered …
patients> 60 years of age with acute myeloid leukemia (AML) who were not considered …
Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia
GJ Roboz, MA Knovich, RL Bayer… - Leukemia & …, 2002 - Taylor & Francis
The objective of this work was to determine the safety and efficacy of gemtuzumab
ozogamicin in patients with poor prognosis acute myeloid leukemia (AML). Patients with the …
ozogamicin in patients with poor prognosis acute myeloid leukemia (AML). Patients with the …
Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial
Addition of gemtuzumab ozogamicin (GO) to induction chemotherapy improves outcomes in
older patients with acute myeloid leukemia (AML), but it is uncertain whether a fractionated …
older patients with acute myeloid leukemia (AML), but it is uncertain whether a fractionated …
Sequential administration of gemtuzubab ozogamicin (GO) and intensive chemotherapy for remission induction in previously untreated patients with AML over the age …
S Amadori, R Willemze, S Suciu, F Mandelli… - Blood, 2001 - art.torvergata.it
Abstract Gemtuzumab ozogamicin (CMA-676, Mylotargâ „¢), a conjugate of a humanized
anti-CD33 monoclonal antibody linked to the cytotoxic antibiotic calicheamicin, has shown …
anti-CD33 monoclonal antibody linked to the cytotoxic antibiotic calicheamicin, has shown …
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia
PF Bross, J Beitz, G Chen, XH Chen, E Duffy… - Clinical cancer …, 2001 - AACR
Abstract Purpose: Gemtuzumab ozogamicin (Mylotarg; Wyeth Laboratories, Philadelphia,
PA) consists of a semisynthetic derivative of calicheamicin, a cytotoxic antibiotic linked to a …
PA) consists of a semisynthetic derivative of calicheamicin, a cytotoxic antibiotic linked to a …
Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse
MS Berger, LH Leopold, JA Dowell… - Investigational new …, 2002 - Springer
This paper discusses background informationand the body of clinical data that has
beenaccumulated to demonstrate the efficacy andsafety of gemtuzumab ozogamicin …
beenaccumulated to demonstrate the efficacy andsafety of gemtuzumab ozogamicin …